Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Exploring interactions between Blastocystis sp., Strongyloides spp. and the gut microbiomes of wild chimpanzees in Senegal.

Renelies-Hamilton J, Noguera-Julian M, Parera M, Paredes R, Pacheco L, Dacal E, Saugar JM, Rubio JM, Poulsen M, Köster PC, Carmena D.

Infect Genet Evol. 2019 Oct;74:104010. doi: 10.1016/j.meegid.2019.104010. Epub 2019 Aug 20.

PMID:
31442596
2.

Evolution of the gut microbiome following acute HIV-1 infection.

Rocafort M, Noguera-Julian M, Rivera J, Pastor L, Guillén Y, Langhorst J, Parera M, Mandomando I, Carrillo J, Urrea V, Rodríguez C, Casadellà M, Calle ML, Clotet B, Blanco J, Naniche D, Paredes R.

Microbiome. 2019 May 11;7(1):73. doi: 10.1186/s40168-019-0687-5.

3.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

4.

Bioinformatic data processing pipelines in support of next-generation sequencing-based HIV drug resistance testing: the Winnipeg Consensus.

Ji H, Enns E, Brumme CJ, Parkin N, Howison M, Lee ER, Capina R, Marinier E, Avila-Rios S, Sandstrom P, Van Domselaar G, Harrigan R, Paredes R, Kantor R, Noguera-Julian M.

J Int AIDS Soc. 2018 Oct;21(10):e25193. doi: 10.1002/jia2.25193.

5.

Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.

Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Kityo C, Steegen K, Naniche D, Clotet B, Rinke de Wit TF, Paredes R; PanAfrican Studies to Evaluate Resistance.

Lancet HIV. 2018 Nov;5(11):e638-e646. doi: 10.1016/S2352-3018(18)30177-2. Epub 2018 Sep 30.

PMID:
30282603
6.

Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection.

Guillén Y, Noguera-Julian M, Rivera J, Casadellà M, Zevin AS, Rocafort M, Parera M, Rodríguez C, Arumí M, Carrillo J, Mothe B, Estany C, Coll J, Bravo I, Herrero C, Saz J, Sirera G, Torrella A, Navarro J, Crespo M, Negredo E, Brander C, Blanco J, Calle ML, Klatt NR, Clotet B, Paredes R.

Mucosal Immunol. 2019 Jan;12(1):232-246. doi: 10.1038/s41385-018-0083-7. Epub 2018 Aug 31.

PMID:
30171206
7.

Balances: a New Perspective for Microbiome Analysis.

Rivera-Pinto J, Egozcue JJ, Pawlowsky-Glahn V, Paredes R, Noguera-Julian M, Calle ML.

mSystems. 2018 Jul 17;3(4). pii: e00053-18. doi: 10.1128/mSystems.00053-18. eCollection 2018 Jul-Aug.

8.

Etiological Characterization of the Cutaneous Ulcer Syndrome in Papua New Guinea Using Shotgun Metagenomics.

Noguera-Julian M, González-Beiras C, Parera M, Ubals M, Kapa A, Paredes R, Mitjà O.

Clin Infect Dis. 2019 Jan 18;68(3):482-489. doi: 10.1093/cid/ciy502.

PMID:
29917039
9.

HIV drug resistance patterns in pregnant women using next generation sequence in Mozambique.

Rupérez M, Noguera-Julian M, González R, Maculuve S, Bellido R, Vala A, Rodríguez C, Sevene E, Paredes R, Menéndez C.

PLoS One. 2018 May 9;13(5):e0196451. doi: 10.1371/journal.pone.0196451. eCollection 2018.

10.

Benzyl-2-Acetamido-2-Deoxy-α-d-Galactopyranoside Increases Human Immunodeficiency Virus Replication and Viral Outgrowth Efficacy In Vitro.

Olvera A, Martinez JP, Casadellà M, Llano A, Rosás M, Mothe B, Ruiz-Riol M, Arsequell G, Valencia G, Noguera-Julian M, Paredes R, Meyerhans A, Brander C.

Front Immunol. 2018 Jan 26;8:2010. doi: 10.3389/fimmu.2017.02010. eCollection 2017.

11.

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.

Inzaule SC, Hamers RL, Noguera-Julian M, Casadellà M, Parera M, Rinke de Wit TF, Paredes R.

J Antimicrob Chemother. 2018 May 1;73(5):1167-1172. doi: 10.1093/jac/dky005.

PMID:
29462322
12.

Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.

Noguera-Julian M, Edgil D, Harrigan PR, Sandstrom P, Godfrey C, Paredes R.

J Infect Dis. 2017 Dec 1;216(suppl_9):S829-S833. doi: 10.1093/infdis/jix397.

13.

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.

Rosás-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobarsí P, Gomez CE, Esteban M, Jímenez JL, García F, Blanco J, Martinez-Picado J, Paredes R, Brander C.

PLoS One. 2017 Sep 27;12(9):e0184929. doi: 10.1371/journal.pone.0184929. eCollection 2017.

14.

Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers.

Vesterbacka J, Rivera J, Noyan K, Parera M, Neogi U, Calle M, Paredes R, Sönnerborg A, Noguera-Julian M, Nowak P.

Sci Rep. 2017 Jul 24;7(1):6269. doi: 10.1038/s41598-017-06675-1.

15.

Oral microbiome in HIV-associated periodontitis.

Noguera-Julian M, Guillén Y, Peterson J, Reznik D, Harris EV, Joseph SJ, Rivera J, Kannanganat S, Amara R, Nguyen ML, Mutembo S, Paredes R, Read TD, Marconi VC.

Medicine (Baltimore). 2017 Mar;96(12):e5821. doi: 10.1097/MD.0000000000005821.

16.

Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death.

Casadellà M, Cozzi-Lepri A, Phillips A, Noguera-Julian M, Bickel M, Sedlacek D, Zilmer K, Clotet B, Lundgren JD, Paredes R; EuroSIDA in EuroCOORD.

PLoS One. 2017 Jan 27;12(1):e0166613. doi: 10.1371/journal.pone.0166613. eCollection 2017.

17.

Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.

Puertas MC, Noguera-Julian M, Massanella M, Pou C, Buzon MJ, Clotet B, Stevenson M, Paredes R, Blanco J, Martinez-Picado J.

Retrovirology. 2016 Aug 2;13(1):51. doi: 10.1186/s12977-016-0282-9.

18.

Whole-Genome Sequencing of Two Bartonella bacilliformis Strains.

Guillen Y, Casadellà M, García-de-la-Guarda R, Espinoza-Culupú A, Paredes R, Ruiz J, Noguera-Julian M.

Genome Announc. 2016 Jul 7;4(4). pii: e00659-16. doi: 10.1128/genomeA.00659-16.

19.

Computational Prediction of HIV-1 Resistance to Protease Inhibitors.

Hosseini A, Alibés A, Noguera-Julian M, Gil V, Paredes R, Soliva R, Orozco M, Guallar V.

J Chem Inf Model. 2016 May 23;56(5):915-23. doi: 10.1021/acs.jcim.5b00667. Epub 2016 May 5.

PMID:
27082876
20.

Gut Microbiota Linked to Sexual Preference and HIV Infection.

Noguera-Julian M, Rocafort M, Guillén Y, Rivera J, Casadellà M, Nowak P, Hildebrand F, Zeller G, Parera M, Bellido R, Rodríguez C, Carrillo J, Mothe B, Coll J, Bravo I, Estany C, Herrero C, Saz J, Sirera G, Torrela A, Navarro J, Crespo M, Brander C, Negredo E, Blanco J, Guarner F, Calle ML, Bork P, Sönnerborg A, Clotet B, Paredes R.

EBioMedicine. 2016 Jan 28;5:135-46. doi: 10.1016/j.ebiom.2016.01.032. eCollection 2016 Mar.

21.

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.

Casadellà M, Noguera-Julian M, Sunpath H, Gordon M, Rodriguez C, Parera M, Kuritzkes DR, Marconi VC, Paredes R.

AIDS. 2016 Apr 24;30(7):1137-40. doi: 10.1097/QAD.0000000000001033.

22.

Mutations Related to Antiretroviral Resistance Identified by Ultra-Deep Sequencing in HIV-1 Infected Children under Structured Interruptions of HAART.

Vazquez-Guillen JM, Palacios-Saucedo GC, Rivera-Morales LG, Garcia-Campos J, Ortiz-Lopez R, Noguera-Julian M, Paredes R, Vielma-Ramirez HJ, Ramirez TJ, Chavez-Garcia M, Lopez-Guillen P, Briones-Lara E, Sanchez-Sanchez LM, Vazquez-Martinez CA, Rodriguez-Padilla C.

PLoS One. 2016 Jan 25;11(1):e0147591. doi: 10.1371/journal.pone.0147591. eCollection 2016.

23.

Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.

Noguera-Julian M, Cozzi-Lepri A, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Metzner KJ, Paredes R; CHAIN Minority HIV-1 Variants Working group.

Clin Microbiol Infect. 2016 Feb;22(2):191-200. doi: 10.1016/j.cmi.2015.10.004. Epub 2015 Oct 23.

24.

Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.

Casadellà M, Manzardo C, Noguera-Julian M, Ferrer E, Domingo P, Pérez-Álvarez S, Podzamczer D, Plana M, Clotet B, Gatell JM, Miró JM, Paredes R; ADVANZ and ADVANZ-3 Investigators.

AIDS. 2015 Jul 31;29(12):1493-504. doi: 10.1097/QAD.0000000000000748.

PMID:
26244389
25.

Primary resistance to integrase strand-transfer inhibitors in Europe.

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM; SPREAD programme.

J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.

PMID:
26188038
26.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing.

Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; CHAIN Minority HIV-1 Variants Working Group.

J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 Oct 21.

27.

Decreased phenotypic susceptibility to etravirine in patients with predicted genotypic sensitivity.

Agneskog E, Nowak P, Maijgren Steffensson C, Casadellà M, Noguera-Julian M, Paredes R, Källander CF, Sönnerborg A.

PLoS One. 2014 Jul 7;9(7):e101508. doi: 10.1371/journal.pone.0101508. eCollection 2014.

28.

Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing.

Pou C, Noguera-Julian M, Pérez-Álvarez S, García F, Delgado R, Dalmau D, Álvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibáñez L, Rodríguez C, Casadellà M, Santos JR, Ruiz L, Clotet B, Paredes R.

Clin Infect Dis. 2014 Aug 15;59(4):578-88. doi: 10.1093/cid/ciu287. Epub 2014 May 29.

PMID:
24879788
29.

Stable HIV-1 integrase diversity during initial HIV-1 RNA decay suggests complete blockade of plasma HIV-1 replication by effective raltegravir-containing salvage therapy.

Noguera-Julian M, Casadellà M, Pou C, Rodríguez C, Pérez-Álvarez S, Puig J, Clotet B, Paredes R.

Virol J. 2013 Dec 5;10:350. doi: 10.1186/1743-422X-10-350.

30.

No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing.

Franco S, Casadellà M, Noguera-Julian M, Clotet B, Tural C, Paredes R, Martinez MA.

J Clin Virol. 2013 Dec;58(4):726-9. doi: 10.1016/j.jcv.2013.09.022. Epub 2013 Oct 3.

PMID:
24140031
31.

HIV-1 tropism testing in subjects achieving undetectable HIV-1 RNA: diagnostic accuracy, viral evolution and compartmentalization.

Pou C, Codoñer FM, Thielen A, Bellido R, Pérez-Álvarez S, Cabrera C, Dalmau J, Curriu M, Lie Y, Noguera-Julian M, Puig J, Martínez-Picado J, Blanco J, Coakley E, Däumer M, Clotet B, Paredes R.

PLoS One. 2013 Aug 1;8(8):e67085. doi: 10.1371/journal.pone.0067085. Print 2013.

32.

Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.

Bonjoch A, Pou C, Pérez-Álvarez N, Bellido R, Casadellà M, Puig J, Noguera-Julian M, Clotet B, Negredo E, Paredes R.

J Antimicrob Chemother. 2013 Jun;68(6):1382-7. doi: 10.1093/jac/dks539. Epub 2013 Jan 25.

PMID:
23354282

Supplemental Content

Loading ...
Support Center